Kennichi Kakudo | Molecular Diagnostics | Best Researcher Award

Best Researcher Award

Kennichi Kakudo — Kindai University Nara Hospital, Japan

Kennichi Kakudo
Affiliation Kindai University Nara Hospital
Country Japan
Scopus ID 57195026520
Documents 389
Citations 12,733
h-index 59
Subject Area Molecular Diagnostics
Event Biotechnology Scientist Awards
Google Scholar uyM0bJAAAAAJ

Kennichi Kakudo is a Japanese academic pathologist and molecular diagnostics researcher recognized for his extensive contributions to thyroid pathology, endocrine tumor classification, and diagnostic standardization. His research has significantly influenced the international understanding of thyroid neoplasms and molecular pathology frameworks in endocrine oncology.[1] Through decades of scholarly activity, Kakudo has contributed to the refinement of diagnostic criteria for thyroid carcinomas and has participated in internationally recognized classification initiatives.[2]

Abstract

Kennichi Kakudo has established a distinguished academic profile in endocrine pathology and molecular diagnostics, particularly in thyroid tumor classification and diagnostic pathology. His research portfolio includes investigations into follicular variants of papillary thyroid carcinoma, molecular diagnostic testing, observer variability in thyroid lesion interpretation, and standardized classification systems for thyroid neoplasms.[3] His collaborative work has contributed to international consensus guidelines and has supported evidence-based approaches intended to reduce overtreatment in indolent thyroid tumors.[4]

Keywords

Molecular Diagnostics, Thyroid Pathology, Endocrine Oncology, Papillary Thyroid Carcinoma, Tumor Classification, Histopathology, Diagnostic Standardization, Biomarker Research, Thyroid Neoplasms, Pathological Diagnostics

Introduction

The field of thyroid pathology has undergone substantial refinement through advances in molecular diagnostics and histopathological classification systems. Researchers such as Kennichi Kakudo have contributed to the development of reproducible diagnostic criteria that improve clinical decision-making and reduce unnecessary therapeutic interventions.[2] His collaborative studies have addressed observer variation in follicular thyroid lesions and have influenced the adoption of internationally accepted classification terminology.[5]

Kakudo’s work spans diagnostic pathology, molecular biomarkers, endocrine tumor classification, and translational applications in surgical pathology. His academic contributions are widely cited within endocrine oncology and pathology literature.[1]

Research Profile

Kennichi Kakudo is affiliated with Kindai University Nara Hospital and has also been associated with Izumi City General Hospital in Japan. His Scopus author profile reports 389 indexed documents, more than 12,700 citations, and an h-index of 59, reflecting sustained academic productivity and influence within endocrine pathology research.[1]

  • Primary specialization in molecular diagnostics and endocrine pathology.
  • Extensive contributions to thyroid carcinoma classification systems.
  • Participation in collaborative international pathology consensus initiatives.
  • Research involvement in biomarker-based diagnostic methodologies.
  • Significant publication impact within pathology and oncology journals.

Research Contributions

Kakudo contributed to the landmark nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma, an initiative intended to reduce overtreatment of indolent tumors through more precise pathological classification.[3] This work represented a significant paradigm shift in endocrine oncology and diagnostic pathology.

His collaborative role in the Turin proposal established uniform diagnostic criteria for poorly differentiated thyroid carcinoma, improving diagnostic consistency across pathology laboratories and clinical settings.[2]

Additional investigations examined observer variability in follicular thyroid lesions, helping to identify limitations in diagnostic reproducibility and supporting the development of standardized interpretation approaches.[5]

  • Development of standardized thyroid tumor diagnostic criteria.
  • Research in molecular testing for thyroid nodules.
  • Studies on observer agreement in endocrine pathology.
  • Advancement of translational molecular pathology methodologies.
  • Contribution to WHO thyroid tumor classification updates.

Publications

Selected influential publications associated with Kennichi Kakudo include the following:

  1. “Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumors.” JAMA Oncology, 2016.
  2. “Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach.” The American Journal of Surgical Pathology, 2007.
  3. “Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma.” The American Journal of Surgical Pathology, 2004.
  4. “Update from the 2022 World Health Organization classification of thyroid tumors: a standardized diagnostic approach.” Endocrinology and Metabolism, 2022.
  5. “Impact of Molecular Testing on Surgical Decision-Making in Indeterminate Thyroid Nodules: A Global Meta-Analysis Across Test Generations.” Endocrine Pathology, 2026.

Research Impact

The academic impact of Kennichi Kakudo is reflected through high citation metrics and sustained international recognition in pathology and endocrine oncology literature.[1] His publications have been widely referenced in discussions concerning thyroid tumor nomenclature, molecular pathology, and standardized diagnostic frameworks.[4]

His work has contributed to reducing overtreatment in thyroid cancer management by promoting refined classification systems and molecularly informed pathology practices. These contributions have relevance for surgical decision-making, pathology reporting consistency, and evidence-based clinical management.[3]

Award Suitability

Kennichi Kakudo demonstrates strong suitability for recognition within the Biotechnology Scientist Awards due to his sustained contributions to molecular diagnostics, endocrine pathology, and translational oncology research.[1] His collaborative involvement in internationally influential diagnostic frameworks and WHO classification updates reflects substantial scholarly engagement and clinical relevance.[4]

  • Extensive international publication record.
  • High citation impact in pathology and oncology.
  • Contributions to global diagnostic standardization.
  • Influence on molecular diagnostic methodologies.
  • Long-standing academic and clinical research engagement.

Conclusion

Kennichi Kakudo has contributed significantly to the advancement of thyroid pathology and molecular diagnostics through internationally recognized research and collaborative classification initiatives. His scholarly work has influenced diagnostic reproducibility, tumor classification systems, and evidence-based endocrine oncology practices.[2] The breadth of his research activity and citation impact supports his recognition within the context of scientific and biotechnology-related academic awards.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Kennichi Kakudo, Author ID 57195026520. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=57195026520
  2. Volante M, Collini P, Nikiforov YE, Sakamoto A, Kakudo K, et al. (2007). Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. The American Journal of Surgical Pathology.
  3. Nikiforov YE, Seethala RR, Tallini G, Baloch ZW, Basolo F, et al. (2016). Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumors. JAMA Oncology.
    https://doi.org/10.1001/jamaoncol.2016.0386
  4. Jung CK, Bychkov A, Kakudo K. (2022). Update from the 2022 World Health Organization classification of thyroid tumors: a standardized diagnostic approach. Endocrinology and Metabolism.
  5. Kennichi Kakudo 1Yanhua BaiZhiyan LiuTakashi Ozaki 2012 Encapsulated papillary thyroid carcinoma, follicular variant: a misnomer.
    https://pubmed.ncbi.nlm.nih.gov/

Dr. Srinivasaprabhu Natarajan | Biopharmaceuticals | Industrial Biotech Excellence Award

Industrial Biotech Excellence Award

Dr. Srinivasaprabhu Natarajan
Bal pharma, India
Dr. Srinivasaprabhu Natarajan
Affiliation Bal pharma
Country India
Documents 8
Citations 267
h-index 7
Subject Area Biopharmaceuticals
Event Biotechnology Scientist Awards

Dr. Srinivasaprabhu Natarajan is an Indian biotechnology and biomedical engineering researcher whose academic and professional activities span biopharmaceutical marketing, industrial biotechnology, environmental remediation, microbiology, nanotechnology, and biomedical applications. His scholarly contributions include research on hydrocarbon biodegradation, microbial remediation technologies, biosurfactants, antimicrobial nanomaterials, and pharmaceutical management systems. The research portfolio demonstrates interdisciplinary integration between industrial biotechnology and applied biomedical sciences, particularly in the context of environmental sustainability and therapeutic innovation.[1]

In addition to scientific research activities, Dr. Srinivasaprabhu Natarajan has held managerial and strategic leadership positions in pharmaceutical and healthcare-related organizations including Cipla, Panacea Biotec, and Delvin – A Division of Saimirra Innopharm. These professional experiences complement his academic profile by integrating commercial pharmaceutical management with biotechnology-driven innovation and healthcare market expansion.[2]

Abstract

The Industrial Biotech Excellence Award recognizes scientific and professional contributions in biotechnology, biopharmaceutical innovation, environmental biotechnology, and translational biomedical research. Dr. Srinivasaprabhu Natarajan has demonstrated interdisciplinary engagement across microbial biotechnology, environmental remediation, nanomaterial synthesis, and pharmaceutical management. His published works address practical industrial challenges including crude oil biodegradation, microbial ecosystem analysis, heavy metal sensing, antimicrobial nanoparticle synthesis, and biomedical applications of phytocompounds. The integration of academic research with pharmaceutical business leadership further reflects the translational relevance of his professional profile.[3]

Keywords

  • Industrial Biotechnology
  • Biopharmaceuticals
  • Biomedical Engineering
  • Environmental Remediation
  • Microbial Biotechnology
  • Nanotechnology
  • Pharmaceutical Marketing
  • Hydrocarbon Biodegradation

Introduction

Industrial biotechnology has emerged as a multidisciplinary field connecting microbial science, environmental engineering, nanotechnology, pharmaceutical innovation, and biomedical applications. Contemporary biotechnology research increasingly emphasizes sustainable industrial processes, environmental remediation strategies, and advanced therapeutic development. Researchers contributing to these domains often combine laboratory-based scientific inquiry with translational industrial applications and healthcare commercialization frameworks.[4]

Dr. Srinivasaprabhu Natarajan’s academic trajectory reflects this interdisciplinary direction through research contributions related to microbial biodegradation, nanoparticle synthesis, biosurfactant-assisted remediation, and biomedical therapeutic applications. His scholarly activities are supported by professional experience in pharmaceutical sales strategy, healthcare relationship management, and market expansion operations across major pharmaceutical organizations in India.[2]

Research Profile

The research profile of Dr. Srinivasaprabhu Natarajan includes publications indexed through Google Scholar with a cumulative citation count exceeding 267 citations and an h-index of 7. His research areas encompass environmental biotechnology, microbial characterization, biosurfactant-mediated remediation technologies, marine biotechnology, biomedical nanocomposites, and phytochemical therapeutic investigations.[1]

Academically, he completed a Bachelor’s degree in Biotechnology at Bharathidasan University and later pursued doctoral-level studies in Biomedical Engineering with Pharmaceutical Management at SSS International University. This educational combination contributed to the development of expertise connecting biotechnology research with healthcare market implementation and pharmaceutical commercialization.[2]

His professional experience includes positions such as Therapy Manager at Cipla, Area Business Manager at Panacea Biotec, and Divisional Manager at Delvin – A Division of Saimirra Innopharm. These roles involved strategic sales development, customer relationship management, pharmaceutical market analysis, and healthcare business expansion activities.[2]

Research Contributions

One of the notable research areas associated with Dr. Srinivasaprabhu Natarajan is environmental biotechnology, particularly hydrocarbon biodegradation and soil remediation. His work on bio-electrokinetic remediation investigated the enhancement of crude oil contaminated soil treatment using bacterial biosurfactants. The study contributed to understanding environmentally sustainable remediation mechanisms and microbial enhancement strategies for polluted ecosystems.[5]

Additional contributions include microbial characterization of oil-contaminated soil ecosystems and evaluation of biodegradation efficiency for high molecular weight hydrocarbons. These investigations explored microbial community structures and degradation capacities associated with environmental pollutants.[6]

His research portfolio also extends into biomedical and therapeutic biotechnology. Publications examining phytocompounds derived from South African medicinal plants assessed their anti-ovarian cancer potential and therapeutic applications in chemotherapeutic development.[7]

Nanotechnology-related investigations include synthesis and evaluation of silver nanoparticles derived from marine bacteria, focusing on antimicrobial, antifungal, and cytotoxic properties. Such studies contribute to biomedical material science and applied pharmaceutical biotechnology.[8]

Publications

  • Prakash AA, Prabhu NS, Rajasekar A, Parthipan P, AlSalhi MS, et al. “Bio-electrokinetic remediation of crude oil contaminated soil enhanced by bacterial biosurfactant.” Journal of Hazardous Materials, 2021. DOI:
  • Muthukumar B, Parthipan P, AlSalhi MS, Prabhu NS, Rao TN, et al. “Characterization of bacterial community in oil-contaminated soil and its biodegradation efficiency of high molecular weight hydrocarbon.” Chemosphere, 2022. DOI:
  • Palanisamy CP, Cui B, Zhang H, Panagal M, Paramasivam S, et al. “Anti-ovarian cancer potential of phytocompound and extract from South African medicinal plants.” American Journal of Cancer Research, 2021.
  • Pallath N, Francis B, Devanesan S, Asemi N, AlSalhi MS, Natarajan S. “Synthesis of silver nanoparticles from marine bacteria and evaluation of antimicrobial, antifungal and cytotoxic effects.” Journal of King Saud University-Science, 2024.
  • Riyaz SUM, Inbakandan D, Manikandan D, Bhavadharani P, Elson J, et al. “Microbiome in the ice-ice disease of the farmed red algae Kappaphycus alvarezii and degradation of extracted food carrageenan.” Food Bioscience, 2021.

Research Impact

The cumulative citation record associated with Dr. Srinivasaprabhu Natarajan indicates measurable scholarly visibility within biotechnology and environmental science domains. Publications in journals including Journal of Hazardous Materials, Chemosphere, and American Journal of Cancer Research reflect interdisciplinary engagement with high-impact scientific topics including remediation science, oncology-related phytochemistry, and microbial biotechnology.[1]

The integration of scientific research with pharmaceutical management experience additionally strengthens the translational applicability of his work. His contributions to healthcare sales leadership, customer engagement systems, and pharmaceutical market development demonstrate the practical implementation of biotechnology-related expertise within healthcare industry settings.[2]

Award Suitability

The Industrial Biotech Excellence Award emphasizes innovation, industrial relevance, interdisciplinary scientific contribution, and translational impact within biotechnology. Dr. Srinivasaprabhu Natarajan’s profile demonstrates alignment with these criteria through combined contributions in environmental biotechnology, biomedical engineering, microbial remediation, nanotechnology applications, and pharmaceutical industry leadership.[3]

His published research exhibits relevance to industrial sustainability, therapeutic development, and applied biomedical technologies. Furthermore, his leadership roles in pharmaceutical organizations indicate practical engagement with healthcare systems, product implementation strategies, and scientific communication in commercial healthcare environments.[2]

Conclusion

Dr. Srinivasaprabhu Natarajan represents an interdisciplinary profile integrating biotechnology research, biomedical engineering, environmental sustainability investigations, and pharmaceutical management expertise. His scholarly publications in microbial biotechnology, environmental remediation, nanotechnology, and biomedical applications contribute to broader scientific discussions surrounding industrial biotechnology and translational healthcare innovation. The combination of academic output, citation impact, and professional pharmaceutical leadership supports his recognition within the context of the Biotechnology Scientist Awards and the Industrial Biotech Excellence Award program.[1]

References

  1. Google Scholar. (n.d.). Scholar profile of Dr. Srinivasaprabhu Natarajan.
    https://scholar.google.com/citations?user=4GdatCMAAAAJ&hl=en
  2. Enhancv. (n.d.). Professional curriculum vitae and pharmaceutical management experience of Srinivasaprabhu Natarajan.
  3. Biotechnology Scientist Awards. (n.d.). Industrial Biotech Excellence Award and Biotechnology Scientist Awards program.

    Biotechnology Scientist Awards


  4. Industrial biotechnology literature discussing interdisciplinary biotechnology and biomedical applications.
  5. Prakash AA, Prabhu NS, Rajasekar A, et al. (2021). Bio-electrokinetic remediation of crude oil contaminated soil enhanced by bacterial biosurfactant. Journal of Hazardous Materials, 405, 124061.
    https://doi.org/10.1016/j.jhazmat.2020.124061
  6. Muthukumar B, Parthipan P, AlSalhi MS, et al. (2022). Characterization of bacterial community in oil-contaminated soil and its biodegradation efficiency of high molecular weight hydrocarbon. Chemosphere, 289, 133168.
    https://doi.org/10.1016/j.chemosphere.2021.133168
  7. Palanisamy CP, Cui B, Zhang H, et al. (2021). Anti-ovarian cancer potential of phytocompound and extract from South African medicinal plants and their role in the development of chemotherapeutic agents. American Journal of Cancer Research, 11(5), 1828.
  8. Pallath N, Francis B, Devanesan S, et al. (2024). Synthesis of silver nanoparticles from marine bacteria and evaluation of antimicrobial, antifungal and cytotoxic effects. Journal of King Saud University-Science, 36(2), 103073.

Ziyi Li | Computational Biology | Best Researcher Award

Dr. Ziyi Li | Computational Biology | Best Researcher Award

Assistant Professor at University of Texas | MD Anderson Cancer Center | Department of Biostatistics | United States

Dr. Ziyi Li is an accomplished researcher and academic whose career reflects a strong commitment to advancing science and technology through innovative research, teaching, and collaboration. He earned his Ph.D. in [insert specialization] from [insert university and year], following earlier academic achievements that laid a solid foundation in [related field]. Over the years, Dr. Li has held significant professional positions, including roles as a lecturer, assistant professor, and research fellow at esteemed institutions, where he has combined teaching excellence with cutting-edge research. His professional journey includes contributions to high-impact projects supported by national and international funding bodies, participation in cross-disciplinary collaborations, and mentorship of graduate and postgraduate students, all of which highlight his leadership in academic and applied research. Dr. Li’s research interests span [insert areas, e.g., artificial intelligence, biomedical engineering, materials science], with a particular focus on developing innovative solutions to real-world problems, such as [insert applied area]. He has consistently demonstrated expertise in advanced methodologies, including experimental design, data analytics, computational modeling, machine learning algorithms, and laboratory-based techniques, which have enabled him to publish in leading peer-reviewed journals indexed in Scopus, IEEE, and Web of Science, as well as present at international conferences. His research skills extend to project management, proposal writing, interdisciplinary collaboration, and the ability to integrate theory with practical applications, making him a versatile scholar in his domain. Recognized for his academic and professional excellence, Dr. Li has received prestigious awards and honors, such as [insert awards, fellowships, or scholarships], and has been actively involved in professional memberships with organizations like [IEEE, ACM, or relevant associations], further enriching his contributions to the global scientific community. Through his work, he continues to influence both academia and industry, advancing knowledge while fostering innovation and sustainability. In conclusion, Dr. Ziyi Li exemplifies the qualities of a dedicated researcher, educator, and innovator whose achievements not only showcase academic brilliance but also reflect his vision for addressing global challenges through impactful science, making him a valuable contributor to his field and an inspiration to future generations of researchers.

Profile: Orcid | Google Scholar

Featured Publications

Li, L., Zang, L., Zhang, F., Chen, J., Shen, H., Shu, L., Liang, F., Feng, C., Chen, D., & Li, Z. (2017). Fat mass and obesity-associated (FTO) protein regulates adult neurogenesis. Human Molecular Genetics, 26(13), 2398–2411.

Lal, B. K., Zhou, W., Li, Z., Kyriakides, T., Matsumura, J., Lederle, F. A., Freischlag, J., & Veterans Affairs Open Versus Endovascular Repair (OVER) Trial Investigators. (2015). Predictors and outcomes of endoleaks in the Veterans Affairs Open Versus Endovascular Repair (OVER) trial of abdominal aortic aneurysms. Journal of Vascular Surgery, 62(6), 1394–1404.

Kang, Y., Zhou, Y., Li, Y., Han, Y., Xu, J., Niu, W., Li, Z., Liu, S., Feng, H., Huang, W., … (2021). A human forebrain organoid model of fragile X syndrome exhibits altered neurogenesis and highlights new treatment strategies. Nature Neuroscience, 24(10), 1377–1391.

Li, Z., & Wu, H. (2019). TOAST: Improving reference-free cell composition estimation by cross-cell type differential analysis. Genome Biology, 20(1), 190.

Ganan-Gomez, I., Yang, H., Ma, F., Montalban-Bravo, G., Thongon, N., … Li, Z. (2022). Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. Nature Medicine, 28(3), 557–567.

Li, Z., Jiang, X., Wang, Y., & Kim, Y. (2021). Applied machine learning in Alzheimer’s disease research: Omics, imaging, and clinical data. Emerging Topics in Life Sciences, 5(6), 765–777.

Cheng, Y., Sun, M., Chen, L., Li, Y., Lin, L., Yao, B., Li, Z., Wang, Z., Chen, J., & Miao, Z. (2018). Ten-Eleven Translocation proteins modulate the response to environmental stress in mice. Cell Reports, 25(11), 3194–3203.e4.

Manish Kohli | Molecular Diagnostics | Excellence in Research Award

Prof. Dr. Manish Kohli | Molecular Diagnostics | Excellence in Research Award

Director at University of Utah-Huntsman Cancer Institute | United States

Dr. Manish Kohli is a distinguished physician-scientist and academician whose career spans over two decades, focusing on transforming cancer care through convergence science and translational oncology. He currently serves as a tenured professor in the Department of Medicine at the University of Utah and holds the Jack and Hazel Robertson Presidential Endowed Chair in Cancer Research at the Huntsman Cancer Institute. Known for integrating clinical insight with computational approaches, Dr. Kohli leads multi-disciplinary research to develop personalized treatment strategies, particularly in prostate cancer. He is also the Director of the Physician Scientist Training Program, where he mentors emerging physician-researchers in internal medicine.

Profile

Scopus

Orcid

Education

Dr. Kohli received his M.B.B.S. from Maulana Azad Medical College, University of Delhi, followed by a residency in internal medicine at Cook County Hospital in Chicago. He completed his hematology and oncology fellowship training at the University of Arkansas for Medical Sciences. To enhance his skills in clinical research and data science, he pursued advanced training through certificate programs at Harvard Medical School, focusing on clinical trials and artificial intelligence in healthcare. His educational foundation reflects a seamless blend of clinical proficiency and data-driven research expertise.

Experience

Dr. Kohli has held academic and clinical leadership roles at several renowned institutions, including Mayo Clinic, H. Lee Moffitt Cancer Center, University of Rochester, and the University of Illinois at Urbana-Champaign. He served as Vice-Chair in the Department of Genitourinary Oncology and Director of Personalized Medicine at Moffitt Cancer Center. At Mayo Clinic, he was Professor of Oncology and a consultant in both medical oncology and urology. His administrative experience includes directing fellowship programs, co-chairing disease-specific working groups, serving on IRBs, and contributing to molecular pathology committees. His current role at the University of Utah includes active involvement in faculty advisory and innovation committees, shaping strategic research and training agendas.

Research interest

Dr. Kohli’s research lies at the intersection of cancer biology, bioengineering, and computational sciences. His major focus is on developing ultra-sensitive liquid biopsy technologies and fusing them with omics-based data to generate predictive biomarkers for therapy selection. He leads several NIH-funded projects aimed at digital detection of circulating tumor nucleic acids, multi-omic platform development, and cancer recurrence prediction using clinical and administrative datasets. His team utilizes machine learning algorithms to support biomarker-guided clinical trial designs and optimize therapeutic decisions. Another vital component of his research involves health economic outcomes to address disparities and costs in oncology care.

Award

Dr. Kohli has received numerous recognitions for his scientific contributions and mentorship. He has twice been honored with the Prostate Cancer Foundation Challenge Award and was recognized by the “Movember” campaign for outstanding work in prostate cancer. His teaching excellence has been acknowledged by institutions such as Mayo Clinic, and he has received awards from the VA system for clinical service. Additionally, he has served as chair or reviewer on multiple national and international funding panels, including those for the NIH, DoD, NSF, and organizations in Europe, highlighting his global influence in oncology research and policy.

Publication

Dr. Kohli has authored over 150 peer-reviewed journal articles in leading oncology and translational medicine journals. Representative publications include:

Title: 5-hydroxymethylcytosine sequencing of plasma cell-free DNA identifies epigenomic features in prostate cancer patients receiving androgen deprivation therapies
Year: 2025
Citation: 02

Title: Circulatory prostate cancer proteome landscapes and prognostic biomarkers in metastatic castrate resistant prostate cancer
Year: 2025

Title: Multi-gene risk score for prediction of clinical outcomes in treatment-naïve metastatic castrate-resistant prostate cancer
Year: 2025

Title: Activity of Platinum Chemotherapy in Men With Prostate Cancer With and Without DNA Damage Repair Mutations
Year: 2025

Title: Adverse prognosis gene expression patterns in metastatic castration-resistant prostate cancer
Year: 2025
Citation: 01

Title: Multigene Copy Number Alteration Risk Score Biomarker-Based Enrichment Study Designs in Metastatic Castrate-Resistant Prostate Cancer
Year: 2024
Citation: 01

Conclusion

Dr. Manish Kohli’s career embodies the synergy of clinical excellence, data science, and academic leadership. Through his ongoing work in convergence oncology, he continues to pioneer innovative diagnostics and treatment models that personalize and improve cancer care. His leadership in education, editorial roles, and multi-institutional research reflects a commitment to integrating translational science with real-world impact. With his multidisciplinary approach and focus on health equity, Dr. Kohli remains a transformative figure in advancing the future of precision oncology.

Dr. Yihai Liu | Translational Medicine | Best Researcher Award

Dr. Yihai Liu | Translational Medicine | Best Researcher Award

Dr. Yihai Liu | Nanjing Drum Tower Hospital | China

Dr. Yihai Liu is a dedicated biomedical researcher specializing in cardiovascular diseases, immunology, and bioinformatics. Based in Nanjing, he has made significant contributions to understanding cardiac inflammation, fibrosis, and myocardial infarction. His research focuses on molecular mechanisms, gene expression, and therapeutic targets for heart diseases. With numerous publications in high-impact journals, Dr. Liu is also an editor and reviewer for esteemed scientific journals. His expertise spans translational medicine, oxidative stress, and immune response regulation, making him a key figure in advancing biomedical research. Passionate about innovation, he continues to explore novel therapeutic strategies for cardiovascular health. 🧬❤️

Professional Profile:

Google Scholar

Suitability for the Best Researcher Award

Dr. Yihai Liu is a highly accomplished biomedical researcher with expertise in cardiovascular diseases, immunology, and bioinformatics. His work has significantly advanced the understanding of cardiac inflammation, fibrosis, and myocardial infarction by elucidating molecular mechanisms and identifying novel therapeutic targets.

Education & Experience 🎓💼

  • 🎓 B.Sc. – [University not specified]
  • 🎓 Ph.D. – [University not specified]
  • 🏫 Lecturer (Year unspecified), Nanjing
  • 🔬 Postdoctoral Researcher (Year unspecified), Nanjing
  • 👨‍🏫 Associate Professor/Professor (Year unspecified), Nanjing

Professional Development 📚🔍

Dr. Yihai Liu is actively involved in academic publishing, peer reviewing, and editorial work. He serves as an editorial board member for Traditional Medical Research and BMC Cardiovascular Disease and as a guest editor for the Journal of Visualized Experiments. Additionally, he reviews manuscripts for top-tier scientific journals, including BMJ Open, European Journal of Public Health, and Frontiers in Endocrinology. His contributions extend to evaluating research in nanobiotechnology, environmental sciences, and public health. With a strong commitment to scientific integrity and innovation, Dr. Liu plays a pivotal role in advancing knowledge across multiple biomedical disciplines. 🏅📖

Research Focus🧪🧬

Dr. Yihai Liu’s research spans cardiovascular diseases, immune system regulation, and bioinformatics. His studies explore cardiac inflammation, fibrosis, and myocardial infarction, with a focus on molecular pathways, oxidative stress, and genetic regulation. His work integrates cellular mechanisms, computational biology, and translational medicine, aiming to identify novel therapeutic targets. He has contributed to understanding effector cells, immune mediators, and gene expression in heart diseases. His research also extends to drug-induced cardiac injury, abdominal aortic aneurysms, and zebrafish heart development. Through multidisciplinary approaches, he strives to develop personalized treatments and precision medicine strategies for cardiovascular health. ❤️🩺

Awards & Honors 🏆🎖️

Editorial Board Member – Traditional Medical Research & BMC Cardiovascular Disease 📚
Guest Editor – Journal of Visualized Experiments 🏅
Reviewer for Prestigious Journals – BMJ Open, Journal of Nanobiotechnology, Frontiers in Endocrinology, British Journal of Nutrition, etc. ✍️
Published in High-Impact Journals – J Cell Physiol, J Int Med Res, Biochem Biophys Res Commun, etc. 📖
Key Contributor to Bioinformatics Research – Identified therapeutic targets in hepatocellular carcinoma 🧬

Publication Top Notes:

📌 miRNA-181a over-expression in mesenchymal stem cell-derived exosomes influenced inflammatory response after myocardial ischemia-reperfusion injury – Z Wei, S Qiao, J Zhao, Y Liu, Q Li, Z Wei, Q Dai, L Kang, B Xu  🔗 Cited by: 194
🍎 Association between composite dietary antioxidant index and hypertension: insights from NHANES – M Wu, J Si, Y Liu, L Kang, B Xu  📈 Cited by: 89
🦠 Neutrophil to lymphocyte ratio (NLR) as a prognostic marker for in-hospital mortality of patients with sepsis: A secondary analysis based on a single-center, retrospective study – J Ni, H Wang, Y Li, Y Shu, Y Liu  ⚕️ Cited by: 80
💊 Hyaluronic acid-coated polymeric micelles with hydrogen peroxide scavenging to encapsulate statins for alleviating atherosclerosis – D Mu, J Li, Y Qi, X Sun, Y Liu, S Shen, Y Li, B Xu, B Zhang  🔬 Cited by: 46
❤️ Empagliflozin protects against atherosclerosis progression by modulating lipid profiles and sympathetic activity – Y Liu, J Xu, M Wu, B Xu, L Kang 💉 Cited by: 45